Kernal Biologics YC 지원서

Summer 2020Active

Kernal Biologics은(는) Summer 2020 배치에서 Healthcare 회사로 Y Combinator를 거쳤습니다. 아래에는 회사의 사업 내용, 창립자, 그리고 실제 YC 양식에 맞춰 재구성한 YC 지원서가 있습니다.

YC 배치: Summer 2020
산업: HealthcareTherapeutics
팀 규모: 20
상태: Active
출시됨: 2020

창업자

Yusuf ErkulFounder
Jeff OzdemirFounder
Burak YILMAZFounder

Kernal Biologics의 사업 내용

Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. Sr. VP of R&D Manfred Kraus is a leader in immuno-oncology, who was most recently Scientific Sr. Director at Bristol-Myers Squibb (BMS).

Kernal Biologics의 YC 지원서, 재구성됨

Y Combinator 지원

Kernal Biologics, Summer 2020 기수. 공개 데이터를 기반으로 작성된 실제 지원 질문.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Kernal Biologics

Describe what your company does in 50 characters or less.

mRNA 2.0 therapies targeting specific cells

What is your company going to make? Please describe your product and what it does or will do.

We're building selective mRNA-LNP immunotherapies that deliver mRNA precisely to specific immune cells. Our lead program, KR-402, targets T cells to program CAR-T therapies directly in the body and can deplete B cells within a week. This lets us treat cancer and autoimmune diseases with fewer off-target effects than current mRNA approaches.

Where do you live now, and where would the company be based after YC?

We live in Cambridge, MA, and Kernal is based there. After YC, we'd remain in Cambridge because that's where our team, science, and investors are concentrated.

Explain your decision regarding location.

Cambridge is a biotech hub with access to top academic talent and proximity to investors, which is critical for developing complex mRNA therapeutics. Being near MIT and Harvard also helps us recruit and collaborate on cutting-edge science.

전체 지원서에서 21개의 추가 답변

Founders, Progress, Idea, Equity, Curious, Batch Preference는 전체 버전에 있습니다. 무료 계정을 만들어 YC Insights에서 모든 YC 배치 옆에 열어보세요.

전체 지원 보기

자주 묻는 질문

Kernal Biologics의 실제 YC 지원서인가요?

아닙니다. Y Combinator는 제출된 지원서를 비공개로 유지합니다. 이것은 재구성된 것입니다. 실제 YC 양식 질문에 Kernal Biologics의 공개 데이터(출시 노트, 창업자 배경, 제품 설명)를 기반으로 답변했습니다. Kernal Biologics과 같은 회사가 YC에 어떻게 자신을 소개하는지 보여주며, 그들이 제출한 텍스트는 아닙니다.